Newamsterdam Pharma Co N.V.
SEC CIK 1936258 · NAMS · last insider filing 2026-06-24
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Lange Louis G | Director | filed 2023 - 2026 |
| Kastelein Johannes Jacob Pieter | Director · Chief Scientific Officer | filed 2023 - 2026 |
| Davidson Michael H. | Director · Chief Executive Officer | filed 2023 - 2026 |
| Lewis William | Director | filed 2024 - 2026 |
| Smither John W | Director | filed 2023 - 2026 |
| Gulfo Adele M. | Director | filed 2025 - 2026 |
| Mckenna Mark C. | Director | filed 2024 - 2026 |
| van der Kamp Hilde Johanna | Director | filed 2023 - 2026 |
| Topper James N | Director | filed 2023 - 2025 |
| Audet Juliette Berangere | Director · See Remarks | filed 2023 - 2025 |
| Joustra Wouter | Director | filed 2024 - 2024 |
| Slootweg Hugo Alexander | Director | filed 2023 - 2023 |
| Downing Nicholas | Director | filed 2023 - 2023 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Kooij Louise Frederika | Chief Accounting Officer | filed 2023 - 2026 |
| Somaiya Mayur Ian | Chief Financial Officer | filed 2023 - 2026 |
| Kling Douglas F | Chief Operating Officer | filed 2023 - 2025 |
| Marino Michael F III | See Remarks | filed 2025 - 2025 |
| Jones William A JR | Chief Commercial Officer | filed 2024 - 2025 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.